HALISTER: Alexion CEO Hallal Resigned; Names David Brennan Interim CEO

Alexion CEO Hallal Resigned; Names David Brennan Interim CEO

(Bloomberg) -- Alexion Pharmaceuticals says CEO David Hallal resigned for personal reasons, effective immediately.
  • Names David Brennan as interim CEO, effective immediately; Brennan is former CEO of AstraZeneca PLC and has been a member of ALXN board since July 2014
  • Spencer Stuart has been engaged to commence search for a permanent CEO
  • Also says CFO Vikas Sinha has left ALXN to pursue other opportunities; names David J. Anderson, former CFO of Honeywell, new CFO
  • Says previously announced audit and finance committee investigation is nearing completion; so far, has not identified any facts that require company to update previously reported results
  • ALXN expects to file 10-Q for the period ended September 30, 2016 in January 2017 or earlier
  • Shares halted
  • NOTE: Nov. 9, Alexion Investigating Allegations on Sales Practices Link
  • NOTE: Nov. 10, Alexion’s Sales Probe So Far Suggests Limited Risk: Leerink Link
Alert: HALISTER
Source: BFW (Bloomberg First Word)

Tickers
ALXN US (Alexion Pharmaceuticals Inc)
AZN LN (AstraZeneca PLC)

People
David Hallal (Alexion Pharmaceuticals Inc)
Vikas Sinha (Alexion Pharmaceuticals Inc)

Topics
Who's News - People
Management Changes

To de-activate this alert, click here

UUID: 7947283